ON
← Back to feed
For years, dementia researchers had no answers, but now the word ‘breakthrough’ is on their lips
Australia🩺 HealthCenter

For years, dementia researchers had no answers, but now the word ‘breakthrough’ is on their lips

Recent advancements in dementia research have sparked optimism among scientists and medical professionals. A new blood test has been developed that can detect the disease at a lower cost, offering a more accessible diagnostic option. Additionally, promising new treatments are being explored, which could significantly impact the management and potential cure of dementia. These breakthroughs are considered major developments in the field, potentially changing the approach to diagnosing and treating the condition.

For years, dementia researchers had no answers, but now the word “breakthrough” is on their lips. After decades of stalled progress, the field is experiencing a surge of optimism following recent approvals of groundbreaking treatments and diagnostics. Two drugs capable of modifying Alzheimer’s disease, Australia’s most prevalent form of dementia, were cleared by the country’s medicine regulator, the Therapeutic Goods Administration, last year. Additionally, a blood test that can identify biomarkers up to 20 years before the onset of memory loss with 92% accuracy received approval two months ago. These advancements mark a turning point for a condition once deemed untreatable. Dementia research faced significant challenges over the past two decades. Promising drug trials frequently failed, and a reliable diagnostic tool remained out of reach despite billions of dollars invested. As a result, pharmaceutical companies withdrew from the sector, leaving patients and scientists alike in a difficult position. Dementia has since become Australia’s leading cause of death. However, this stagnation appears to be breaking, with researchers and clinicians expressing cautious enthusiasm about the future. Global efforts to combat dementia are intensifying, with 158 different drugs currently under investigation in 192 clinical trials. These include novel brain-targeted therapies, mRNA vaccines, and repurposed medications such as those used for weight loss and erectile dysfunction. According to University of NSW professor Kaarin Anstey, who serves on the World Health Organization’s dementia panel, the pace of innovation is unprecedented. “It’s like an explosion in developments across the board,” she said. Researchers are also gaining greater insight into risk factors, adding to the sense of optimism within the field. Dr. Emma Devenney, a neurologist, recalled being discouraged from pursuing dementia research early in her career due to its perceived lack of progress. She now sees a shift in direction. “This is changing the trajectory, which we haven’t been able to do until now,” she said. “It’s lovely for patients and their families to have some hope.” Approximately 460,000 Australians live with dementia, a number projected to rise to half a million in the next three years and double to one million by 2061. While Australia's dementia prevalence rate lags behind nations with larger elderly populations like Japan, Germany, and Italy, the Asia-Pacific region faces a looming crisis. Rates are expected to triple by 2050 due to aging demographics and lifestyle changes, potentially accounting for half of all global cases. This does not mean the situation is inevitable, however. Advances in detection and treatment, along with increasing understanding of preventive measures, suggest that dementia might be detected, slowed, or even halted before symptoms manifest. Previously, diagnosing Alzheimer’s required costly and invasive procedures such as lumbar punctures or PET scans. Now, a new blood test known as pTau217 offers similar accuracy but at a much lower cost and faster turnaround time. The test identifies abnormal tau protein levels, a crucial biomarker for Alzheimer’s. Neuroscientist Matthew Kiernan noted that this test empowers both doctors and patients while accelerating research. He anticipates that eventually, it could be available at local blood laboratories. Before these new drugs were approved, individuals suffering from Alzheimer’s had few therapeutic options beyond symptom management. The recently introduced monoclonal antibodies, donanemab and lecanemab, function by engaging the recipient’s immune system to target and reduce amyloid-beta plaques, a hallmark of the disease. These treatments represent a fundamental change in how Alzheimer’s is approached medically.

How this report was made. Objective News wrote this report from 2 source articles, using AI-assisted synthesis under our methodology. It is our own text, not a copy of any single outlet. Read our methodology.

Responsible editor: Matej BašaSpotted an error? Report it

Go to the primary sources (1)

The official sources this coverage is built on. Read them directly to bypass framing.

2 reports

The Age logoThe AgeIndependentCenterFactual: no official source document/info detectedObjective 80
For years, dementia researchers had no answers, but now the word ‘breakthrough’ is on their lips

Recent advancements in dementia research have sparked optimism among scientists and medical professionals. A new blood test has been developed that can detect the disease at a lower cost, offering a more accessible diagnostic option. Additionally, promising new treatments are being explored, which could significantly impact the management and potential cure of dementia. These breakthroughs are considered major developments in the field, potentially changing the approach to diagnosing and treating the condition.

Bias read (Center): The article discusses scientific advancements in dementia research without taking a stance on political issues. It focuses on health-related developments such as a blood test and new treatments, which are not inherently politically charged. There is no indication of bias or framing towards any side.

Why factuality: no official source document/info detected

Why objectivity (80): The tone of both articles is positive and optimistic, using phrases like 'game changers' and 'breakthrough.' However, they remain focused on reporting the developments without injecting personal opinion or bias. The language is professional and does not appear to favor any particular stakeholder or

The Sydney Morning Herald logoThe Sydney Morning HeraldIndependentCenterFactual: no official source document/info detectedObjective 80
For years, dementia researchers had no answers, but now the word ‘breakthrough’ is on their lips

The article discusses recent advancements in dementia research, including a blood test that can cheaply detect the disease and promising new treatments, which are described as potential game-changers in the field.

Bias read (Center): The article presents scientific developments in dementia research without overt ideological framing. While the language suggests optimism about medical progress, there is no clear partisan slant or emphasis on specific political agendas. The focus remains on scientific achievement rather than policy

Why factuality: no official source document/info detected

Why objectivity (80): This article maintains a neutral and informative tone, presenting the developments as significant without overt emotional appeal. It avoids taking sides or expressing personal views, keeping the focus on the facts presented. The language remains objective and aligned with standard journalistic stand

How each side covered it

The same event, grouped by the political lean of the outlets covering it.

How each side covered it

Support independent, bias-aware news and unlock the social pulse, community voting, and every other Supporter feature.

Become a Supporter

Covered around the world

The same event as reported in other countries.

Covered around the world

Support independent, bias-aware news and unlock the social pulse, community voting, and every other Supporter feature.

Become a Supporter

Claims check

Key factual claims, and how many sources assert vs dispute each.

Claims check

Support independent, bias-aware news and unlock the social pulse, community voting, and every other Supporter feature.

Become a Supporter

Keep the news honest.

ObjectiveNews is reader-funded and ad-free — we show you the bias instead of hiding it. Support independent journalism for €4/month.

Become a Supporter

Related stories